Sun Pharmaceutical Industries' (NSE:SUNPHARMA, BOM:524715) consolidated net profit declined to 22.8 billion Indian rupees in the fiscal first quarter ended June 30, against 28.4 billion rupees a year ago.
Earnings per share contracted to 9.5 rupees compared with 11.8 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.
Revenue from operations in fiscal Q1, however, grew to 138.5 billion rupees from 126.5 billion rupees a year ago.
The company's shares were down 1% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。